Xenon Pharmaceuticals Appoints Sonia Graham as CFO to Drive Growth in Biopharma
New CFO Sonia Graham steers Xenon Pharmaceuticals toward growth, bolstering finance, compliance and biopharma innovation.
3 minutes to read
XENON PHARMACEUTICALS INC
Xenon Pharma (XENE): Volatile Stock, Negative P/E, But Strong Market Optimism
Explore Xenon Pharmaceuticals’ biotech journey, stock volatility, and its focus on ion‑channel therapies and gene‑therapy Glybera, plus key financial insights.
2 minutes to read
Xenon Pharmaceuticals Boosts Talent & Stock Momentum with New Equity Grants – Market Grows 9.7%
Explore Xenon Pharmaceuticals’ new equity grants, market rebound, and promising epilepsy data that could drive its biotech future.
2 minutes to read
Xenon Pharmaceuticals Leads the Charge in Gene Therapy with Glybera
Xenon Pharmaceuticals Inc. is a clinical-stage biotech company pioneering gene therapy, particularly with its product Glybera, which aims to treat a rare lipid disorder with a lasting solution.
3 minutes to read
Xenon Pharmaceuticals Inc. Advances in 2025 with Promising Phase 3 Developments in Epilepsy and Psychiatry
Xenon Pharmaceuticals Inc. is making progress in 2025 with promising developments in its clinical-stage endeavors, including advancements in Phase 3 programs for epilepsy and psychiatry.
2 minutes to read